Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV005012223 | SCV005643381 | likely pathogenic | Arthrogryposis, renal dysfunction, and cholestasis 1; Keratoderma-ichthyosis-deafness syndrome, autosomal recessive; Cholestasis, progressive familial intrahepatic, 12 | 2024-04-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005112603 | SCV005780268 | likely pathogenic | not provided | 2024-09-11 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 13 of the VPS33B gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in VPS33B are known to be pathogenic (PMID: 15052268, 16896922). This variant is present in population databases (rs774653538, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with VPS33B-related conditions. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |